*See rebate card for details.
For patients with psoriasis, convenience and cosmetic characteristics of topical treatments are key motivators for continued use1,2
PTCS: Psoriasis Treatment Convenience Scale.
Up to 75% of patients are non-adherent to topical treatments for plaque psoriasis, and the most frequent reasons for discontinuation include poor cosmetic characteristics and time-consuming nature.2,4
Cosmetic acceptability and ease of use affect treatment preference and adherence, with patients generally preferring less messy treatments that are easy to apply.5
Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.
Please see Full Prescribing Information for Wynzora.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
References: 1. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. 2. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(s3):61-67. 3. Data on file. MC2 Therapeutics. 4. Armstrong AW. Practice Gaps: failure to maximize patient adherence strategies in clinical practice. Arch Dermatol. 2010;146(12):1430-1431. 5. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;2(suppl 4):9-14. doi:10.1111/j.1468-3083.2011.04060.x